TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20642391
Drug: Atomoxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine treatment at 40 weeks
Study: 20642391
Drug: Atomoxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine treatment at 8 weeks
Study: 17977190
Drug: Platelet gel
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet gel treatment
Study: 17977190
Drug: No platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: No platelet gel treatment (Control)
Study: 9535315
Drug: Carbamazepine (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (450 mg at 150 mg three times per day, increased as needed)
Study: 9535315
Drug: Carbamazepine (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (after stopping, lactose placebo administered for 3 weeks)
Study: 9535315
Drug: Carbamazepine (second
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (second treatment)
Study: 1106746
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of rimiterol and terbutaline
Study: 26846795
Drug: Dextrose injections
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose injections
Study: 19700470
Drug: Irbesartan 150
Normalized name: irbesartan 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan 150 mg/day followed by 300 mg/day on day 15
Study: 19700470
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg/day followed by 20 mg/day on day 15
Study: 17479947
Drug: Atazanavir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir (400 mg per day or 300/100 mg per day with ritonavir)
Study: 15543343
Drug: Cerivastatin 0.2
Normalized name: cerivastatin 0.2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin 0.2 mg to 0.4 mg daily for 12 weeks
Study: 15543343
Drug: Fenofibrate 250
Normalized name: fenofibrate 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 250 mg daily for 12 weeks
Study: 12867500
Drug: Intracutaneous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracutaneous injection of endogenous PAR‐2 agonists
Study: 12867500
Drug: Local antihistamines
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local antihistamines
Study: 10230458
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy before irradiation
Study: 10230458
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy after irradiation
Study: 10230458
Drug: Radiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy with a gap between treatment fields
Study: 6294770
Drug: Post-cardiac arrest
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-cardiac arrest thiopental loading (30 mg/kg body wt)
Study: 24509407
Drug: High-dose interferon-alpha2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon-alpha2b (HDI) plus GM2-KLH/QS-1 (GMK)
Study: 24509407
Drug: High-dose interferon-alpha2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon-alpha2b (HDI)
Study: 24509407
Drug: GMK (vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMK (vaccine group)
Study: 19171716
Drug: Continuing chemotherapy/cis-RA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuing chemotherapy/cis-RA
Study: 19171716
Drug: Chemotherapy/no cis-RA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy/no cis-RA
Study: 15002538
Drug: L-arginine-hydrochloride (18
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine-hydrochloride (18 g)
Study: 3315761
Drug: Hypoglycaemia induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycaemia induced by insulin-glucose clamp technique (insulin: 2.4 mU/kg/min + glucose at variable rate) after an overnight fast
Study: 3315761
Drug: Hypoglycaemia induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycaemia induced by insulin-glucose clamp technique after 72 hours fasting
Study: 27345636
Drug: Bendamustine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine monotherapy
Study: 22419151
Drug: Acarbose test
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose test formulation (2×50 mg)
Study: 17766766
Drug: Standard, therapist-led
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard, therapist-led group therapy
Study: 15150679
Drug: Dexamethasone (DEXA)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEXA) 2.0 mg
Study: 15150679
Drug: Prednisolone (PRED)
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone (PRED) 12.5 mg
Study: 1562888
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (distensive and nondistensive)
Study: 354827
Drug: alpha-methyldopa up
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-methyldopa up to 500 mg b.i.d.
Study: 354827
Drug: metoprolol up
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol up to 200 mg b.i.d.
Study: 20821373
Drug: PST-OT (Problem-solving
Approvals — FDA: no, EMA: no, PMDA: no
Description: PST-OT (Problem-solving and Occupational Therapy intervention)
Study: 11355097
Drug: 0.1% fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% fluoride varnish application and professional tooth-cleaning, motivation and instruction in oral hygiene (T)
Study: 11355097
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene instruction and supervised toothbrushing once a year (C)
Study: 25467826
Drug: 10-day standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day standard sequential therapy
Study: 25467826
Drug: levofloxacin-containing sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: levofloxacin-containing sequential therapy
Study: 16938120
Drug: Patient self-management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient self-management (PSM) of anticoagulation therapy
Study: 9950107
Drug: Amoxicillin/clavulanate (625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (625 mg every 8 hours for 10 days)
Study: 7567310
Drug: Ceftibuten (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftibuten (9 mg/kg daily for 10 days)
Study: 7567310
Drug: Amoxicillin/clavulanate (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (40 mg/kg/day given every 8 hours for 10 days)
Study: 6996138
Drug: Standardized senna
Normalized name: standardized senna concentrate
DrugBank: Senna leaf (DB15889)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized senna tablets (Senokot; Reckitt & Colman)
Study: 14695410
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g of sucrose
Study: 27125669
Drug: Eribulin mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin mesylate 1.4 mg/m2 as a 2- to 5-min intravenous infusion on days 1 and 8 of each 21-day cycle
Study: 24336820
Drug: Daily co-trimoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily co-trimoxazole (CMX) 800 mg/160 mg
Study: 24336820
Drug: Sulfadoxine-pyrimethamine intermittent
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine-pyrimethamine intermittent preventive treatment (IPT-SP)
Study: 24336820
Drug: Daily co-trimoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily co-trimoxazole (CMX)
Study: 12017952
Drug: Intermittent epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent epidural analgesia with bupivacaine plus intravenous Ketorolaco
Study: 6993548
Drug: Double dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dose of CB-154 (5 mg po) one hour before arginine test
Study: 27872117
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (neoadjuvant long course radiotherapy ± chemotherapy and APER)
Study: 24560173
Drug: DFDBA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFDBA plus lincomycin therapy
Study: 22133470
Drug: Beta-blocker up-titration
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beta-blocker up-titration to 12.5% of target dose
Study: 22133470
Drug: Beta-blocker up-titration
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beta-blocker up-titration to 25% of target dose
Study: 22133470
Drug: Beta-blocker up-titration
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beta-blocker up-titration to 50% of target dose
Study: 22133470
Drug: Beta-blocker up-titration
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beta-blocker up-titration to 100% of target dose
Study: 22133470
Drug: Groups 3/4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Groups 3/4 (50% and 100% target dose)
Study: 22133470
Drug: Groups 1/2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Groups 1/2 (12.5% and 25% target dose)
Study: 17959943
Drug: Greek tsatsiki
Normalized name: Greek pitch
DrugBank: Rosin (DB11165)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Greek tsatsiki with 4.2 g raw garlic (verum)
Study: 17959943
Drug: Daily ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily ingestion of 4.2 g of raw garlic over 1 week
Study: 16296439
Drug: One‐Step (one‐bottle
Approvals — FDA: no, EMA: no, PMDA: no
Description: One‐Step (one‐bottle bonding agent)
Study: 16296439
Drug: Gluma Desensitizer
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gluma Desensitizer (glutaraldehyde‐based agent)
Study: 10217550
Drug: 21 mg/day
Normalized name: nicotine 21 MG/Day 24HR Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 mg/day transdermal nicotine patch (Nicoderm CQ)
Study: 6381610
Drug: HuIFN‐alpha 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HuIFN‐alpha 2 nasal spray (9 X 10(6) international units, three times a day for five days)
Study: 23622801
Drug: 14-day quadruple
Normalized name: HUMAN PULMONARY SURFACTANT-ASSOCIATED PROTEIN D (PSPD, SURFACTANT PROTEIN D, SP-D, COLLECTIN-7, SURFACTANT PROTEIN D), NON-COVALENT QUADRUPLE TRIMER, PRODUCED IN HUMAN MYELOGENOUS LEUKEMIA K562 CELLS, GLYCOFORME ALFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day quadruple therapy (OMAB group) comprising omeprazole 20mg, metronidazole 500 mg, amoxicillin 1g, and bismuth subcitrate 240 mg
Study: 23622801
Drug: 14-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day triple regimen (OCP group) comprising omeprazole 20mg plus clarithromycin 500 mg and penbactam 750 mg
Study: 23622801
Drug: 14-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day triple regimen (OCA group) comprising omeprazole 20mg plus clarithromycin 500 mg and amoxicillin 1g
Study: 12869883
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg once daily for 28 days
Study: 12869883
Drug: Nizatidine 150
Normalized name: nizatidine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 150 mg twice daily for 28 days
Study: 8285627
Drug: Ceftriaxone at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone at 2 g/day for 3 days
Study: 8285627
Drug: Chloramphenicol at
Normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloramphenicol at 50 mg/kg of body weight per day for 14 days
Study: 29745059
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of TNFi treatment
Study: 27791207
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality Reflection Therapy (VRRT)
Study: 18946891
Drug: Treatment in
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in general practice
Study: 8728487
Drug: Melatonin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (5 mg) administered at 1300 h
Study: 8728487
Drug: Melatonin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (5 mg) administered at 1800 h
Study: 1794818
Drug: Sezolamide 1.8%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sezolamide 1.8% twice daily
Study: 6837251
Drug: Flunitrazepam 2
Normalized name: flunitrazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 2 mg perorally the night before operation and diazepam 0.2 mg per kg body weight perorally at 7.00 a.m. on the day of operation
Study: 6837251
Drug: Flunitrazepam 2
Normalized name: flunitrazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam 2 mg perorally the night before operation and morphine/scopolamine i.m. 1 h prior to operation
Study: 6837251
Drug: No flunitrazepam
Normalized name: flunitrazepam
DrugBank: Flunitrazepam (DB01544)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No flunitrazepam given on the night before operation, morphine/scopolamine i.m. 1 h preoperatively
Study: 29992486
Drug: Combined exercise
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined exercise plus diet program (12-week, weekly aerobic exercise, 1200 kcal/day diet)
Study: 29851107
Drug: FMT-S (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMT-S (single faecal infusion via colonoscopy followed by a 14-day vancomycin course)
Study: 29851107
Drug: FMT-M (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMT-M (multiple faecal infusions plus a 14-day vancomycin course)
Study: 29231361
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of ginger-isolated moxibustion and escitalopram (10 mg/day)
Study: 17417658
Drug: Live-attenuated varicella
Normalized name: varicella, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live-attenuated varicella zoster vaccine
Study: 11772824
Drug: 0.075% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.075% ropivacaine with fentanyl 2 microg/mL
Study: 11772824
Drug: 0.075% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.075% bupivacaine with fentanyl 2 microg/mL
Study: 2540788
Drug: Four courses
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four courses of cytotoxic chemotherapy (cyclophosphamide, vincristine, etoposide)
Study: 2540788
Drug: Eight courses
Normalized name: OC Eight
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eight courses of cytotoxic chemotherapy (cyclophosphamide, vincristine, etoposide)
Study: 2540788
Drug: Four courses
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four courses of chemotherapy followed by relapse chemotherapy (methotrexate and doxorubicin)
Study: 2540788
Drug: Eight courses
Normalized name: OC Eight
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eight courses of chemotherapy followed by relapse chemotherapy (methotrexate and doxorubicin)
Study: 1078711
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (coronary bypass)
Study: 28177719
Drug: Polyphenol beverage
Normalized name: Pomegranate Fruit Polyphenol Extract
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyphenol beverage (1-1.5 L/day, approximately 400 mg of gallic acid equivalents per day)
Study: 25116481
Drug: BMS-820836 (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-820836 (0.5 mg)
Study: 25116481
Drug: BMS-820836 (0.1-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-820836 (0.1-4 mg)
Study: 22915051
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL PS yoghurt drink consumed 45 min prior to a solid meal
Study: 22915051
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL PS yoghurt drink consumed during a solid meal
Study: 22915051
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL PS yoghurt drink consumed 45 min after a solid meal
Study: 17135035
Drug: Estradiol 2
Normalized name: estradiol 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol 2 mg/day
Study: 17135035
Drug: Estradiol 2
Normalized name: estradiol 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol 2 mg/day and norethisterone acetate 1 mg/day
Study: 14561021
Drug: IV/PO moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV/PO moxifloxacin 400 mg QD
Study: 14561021
Drug: IV/PO amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV/PO amoxicillin clavulanate 1200/625 mg TID +/- IV/PO clarithromycin 500 mg BID
Study: 8635375
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (4 mg, qid)
Study: 8635375
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium (2 mg, qid)
Study: 1727685
Drug: Naloxone (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.15 mg/kg i.v.)
Study: 1727685
Drug: Naloxone (0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.075 mg/kg i.v.)
Study: 27425824
Drug: NTP-CE (topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTP-CE (topical panthenol-containing emollient)
Study: 22311659
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) applied (670 nm, 5 mW, 2 J/cm², 16 min, 5 days)
Study: 21083596
Drug: rabeprazole 5
Normalized name: RABEprazole 5 mg oral delayed release capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole 5 mg/day
Study: 17470824
Drug: Adalimumab (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (160 mg at week 0 and 80 mg at week 2)
Study: 12000496
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with 1% benzyl benzoate and 1% tannic acid
Study: 12000496
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (first treatment)
Study: 12000496
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (second treatment)
Study: 2729162
Drug: Glucose absorption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose absorption in NIDDM subjects
Study: 2729162
Drug: Glycine absorption
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycine absorption in NIDDM subjects
Study: 2729162
Drug: Glucose absorption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose absorption in healthy volunteers
Study: 2729162
Drug: Glycine absorption
Normalized name: Glycine
DrugBank: Glycine (DB00145)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycine absorption in healthy volunteers
Study: 30034
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Pindolol and 5 mg Clopamid (VKB 105)
Study: 28139100
Drug: Ozurdex® implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozurdex® implant (PRN group)
Study: 28139100
Drug: Ozurdex® implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozurdex® implant (fixed group)
Study: 23381501
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (immediate treatment)
Study: 23381501
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (no treatment for 3 months)
Study: 18206037
Drug: Intracoronary administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary administration of anisodamine (200 microg/ml)
Study: 18206037
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (Control group B)
Study: 18206037
Drug: Intracoronary administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary administration of anisodamine
Study: 9815053
Drug: Intravenous famotidine
Normalized name: Famotidine
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous famotidine (gastric acid inhibition)
Study: 8715223
Drug: Lugol daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lugol daily dressings applied for 10 consecutive days
Study: 340158
Drug: Propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 80 to 160 mg daily
Study: 30565426
Drug: β-alanine (BA)
Normalized name: Alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-alanine (BA) supplementation (12 g/day for 14 days)
Study: 27286893
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept (2 mg)
Study: 24996893
Drug: Aspheric toric
Normalized name: Boric Acid
DrugBank: Boric acid (DB11326)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspheric toric intraocular lens (Lentis L‐312T)
Study: 24996893
Drug: Aspheric nontoric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspheric nontoric intraocular lens (Lentis L‐312) with opposite clear corneal incision (OCCI)
Study: 17587273
Drug: Magnesium oxide
Normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium oxide (50 mg/kg/day)
Study: 11807965
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg hawthorn extract
Study: 11807965
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg Mg
Study: 11807965
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 600 mg Mg and 500 mg hawthorn extract
Study: 88753
Drug: 5‐FU chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU chemotherapy (12 mg/kg daily for 4 days, then 6 mg/kg on alternate days, followed by 12 mg/kg weekly for 1 year)